Arcus Biosciences (RCUS) Equity Average (2018 - 2026)

Arcus Biosciences' Equity Average history runs 9 years deep, the most recent figure standing at $577.5 million for Q1 2026.

• In Q1 2026, Equity Average rose 13.68% year-over-year to $577.5 million; the TTM figure through Mar 2026 stood at $577.5 million (up 13.68% YoY), while the FY2025 annual figure was $558.0 million, up 17.85% from the prior year.
• Equity Average was $577.5 million for Q1 2026 at Arcus Biosciences, up from $533.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $819.5 million in Q1 2022 to a low of $491.0 million in Q4 2023.
• Historically, Equity Average has averaged $604.1 million across 5 years, with a median of $583.0 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Equity Average soared 40.47% in 2022, then dropped 27.58% in 2023.
• A 5-year view of Equity Average shows it stood at $678.0 million in 2022, then slipped by 27.58% to $491.0 million in 2023, then rose by 6.92% to $525.0 million in 2024, then climbed by 1.62% to $533.5 million in 2025, then climbed by 8.25% to $577.5 million in 2026.
• The last three Equity Average figures came in at $577.5 million (Q1 2026), $533.5 million (Q4 2025), and $492.5 million (Q3 2025), per Business Quant data.